GlassScriptPhysician profile
Varendra Jamwant
NPI 1205358777
$3,030.65
in general payments reported to CMS, 2019-2025
16 companies · $169 in 2025
The $169 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,012 · 2020: $93.28 · 2021: $1,613 · 2022: $112 · 2023: $31.50 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $200.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cgg Medical INC | $1,217.21 | 2021-2022 | |
| Organogenesis INC. | $767.87 | 2019-2025 | Affinity |
| Musculoskeletal Transplant Foundation INC. | $162.63 | 2019 | |
| Sanara Medtech INC. | $135.88 | 2025 | Celleraterx |
| Horizon Therapeutics Plc | $125.05 | 2019 | |
| Avinger INC. | $123.87 | 2021 | |
| Osiris Therapeutics INC. | $100.16 | 2019 | |
| Smith+Nephew, INC. | $95.70 | 2021-2023 | Grafix Pl |
| Tenex Health INC. | $93.28 | 2020 | |
| Stryker Corporation | $69.37 | 2019 | |
| Acera Surgical, INC. | $53.33 | 2022 | |
| Kerecis Limited | $21.20 | 2021 | |
| Boston Scientific Corporation | $19.34 | 2021 | |
| Kci USA, INC. | $18.90 | 2021 | |
| Nalu Medical, INC. | $13.62 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acell, INC. | $13.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varendra Jamwant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.